Working… Menu

A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease (NILVAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02017340
Recruitment Status : Completed
First Posted : December 20, 2013
Last Update Posted : March 6, 2017
University of Dublin, Trinity College
Molecular Medicine Ireland LBG
Alzheimer Europe
Archer Pharmaceuticals, Inc.
E-Search Limited
University College Dublin
King's College London
Istituto Di Ricerche Farmacologiche Mario Negri
University Hospital, Lille
University of Ulm
Szeged University
Göteborg University
University College Cork
Aristotle University Of Thessaloniki
Stichting Katholieke Universiteit
Information provided by (Responsible Party):
Prof Brian Lawlor, St. James's Hospital, Ireland

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 16, 2016
Actual Study Completion Date : December 16, 2016

Publications automatically indexed to this study by Identifier (NCT Number):